SU-G-TeP3-15: Radiation Dose Enhancement by Anatase TiO2NPs




This work investigates radiation dose enhancement caused by TiO2 nanoparticles covering entire X-ray energy ranges used in radiation therapy.


Anatase TiO2NPs crystal were synthesised and modified as hydrophilic and hydrophobic to disperse in culture-medium and halocarbons (PRESAGE chemical composition) respectively. TiO2NPs were characterised using TEM, XPS, XRD, TGA and FTIR. Various Concentrations have been utilised for determination of radiation-dose enhancement. This investigation is carried out in two ways; one using PRESAGE dosimeter/phantom and the other is radiobiological and based on in vitro study using two types of cell lines, Human Keratinocyte (HaCaT) and prostate cancer cell lines. The x-ray used are both kilovoltage and megavoltage separately. The prepared PRESAGE dosimeters were scanned using optical CT scanner. Clonogenic and MTS assays were employed for cell cytotoxicity and viability measurements for determination of the levels of dose enhancement.


Significant about (50%, 45%) dose enhancement by TiO2-NPs for kV x-rays is measured in both ways (Presage and Cells study). Slightly more is detected with the cells. However, the dose enhancement with megavoltage beams was insignificant using Presage and under same conditions the cells survival curves indicates around 20% which is relatively high. This difference can only be attributed to some biochemical effects. Such as generation of reactive oxygen species (ROS), this can affect the cells while it can't be detected by Presage. Elevation of hydroxyl radicals (•OH) of many orders is observed with the inclusion of TiO2-NPs in cells-medium.


Dose enhancement inflicted by TiO2-NPs is proven to be significant with megavoltage beams and minimal with kV. The high dose enhancements obtained can be attributed to higher levels of ROS generated. Since MV beams are most commonly used, this research proves potential value for more efficient beam delivery. This has potential to be applied in future clinical radiotherapy applications

The research is supported and funded by RMIT university-Melbourne/Australia